Quick Ratios
Quarterly Results
Profit & Loss
Balance Sheet
Cash Flow
Ratios
Mkt Cap
Market Capitalization
₹4,534Cr
Rev Gr TTM
Revenue Growth TTM
5.66%
Peer Comparison
Compare up to 10 companies side by side across valuation, profitability, and growth.

NEOGEN
VS
| Quarter | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|
|
Growth YoY Revenue Growth YoY% | 30.1 | 11.5 | 9.2 | -11.7 | -2.1 | 9.1 | 19.6 | 22.5 | 1.6 | 3.8 | 7.9 | 9.2 |
| 171 | 137 | 136 | 144 | 164 | 149 | 159 | 167 | 166 | 155 | 179 | 188 |
Operating Profit Operating ProfitCr |
| 16.0 | 17.0 | 16.0 | 12.3 | 17.9 | 17.1 | 17.9 | 17.2 | 17.9 | 16.9 | 14.4 | 14.5 |
Other Income Other IncomeCr | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | -13 | 1 | 2 | 2 |
Interest Expense Interest ExpenseCr | 9 | 11 | 11 | 11 | 10 | 10 | 13 | 13 | 13 | 13 | 19 | 22 |
Depreciation DepreciationCr | 4 | 5 | 6 | 6 | 6 | 7 | 7 | 7 | 7 | 6 | 7 | 7 |
| 21 | 14 | 11 | 6 | 22 | 16 | 15 | 15 | 4 | 14 | 5 | 6 |
| 6 | 4 | 3 | 5 | 6 | 4 | 5 | 5 | 1 | 4 | 2 | 2 |
|
Growth YoY PAT Growth YoY% | -8.5 | -12.2 | -19.8 | -92.8 | 18.3 | 17.6 | 38.4 | 844.3 | -85.8 | -10.6 | -69.3 | -63.1 |
| 7.0 | 5.9 | 4.9 | 0.6 | 8.5 | 6.4 | 5.7 | 5.0 | 1.2 | 5.5 | 1.6 | 1.7 |
| 5.7 | 3.9 | 3.2 | 0.4 | 6.4 | 4.3 | 4.2 | 3.8 | 0.9 | 3.9 | 1.3 | 1.4 |
| Financial Year | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|
|
| | 48.3 | 28.1 | -100.0 | | | 0.7 | 12.6 | 5.2 |
| 132 | 196 | 248 | 0 | 0 | 575 | 581 | 641 | 688 |
Operating Profit Operating ProfitCr |
| 18.0 | 18.2 | 19.0 | | | 16.3 | 15.9 | 17.5 | 15.9 |
Other Income Other IncomeCr | 1 | 1 | 0 | 0 | 0 | 5 | 8 | -10 | -8 |
Interest Expense Interest ExpenseCr | 10 | 12 | 12 | 0 | 0 | 29 | 42 | 49 | 66 |
Depreciation DepreciationCr | 2 | 3 | 5 | 0 | 0 | 16 | 23 | 28 | 27 |
| 17 | 29 | 41 | 0 | 0 | 71 | 53 | 50 | 29 |
| 6 | 8 | 12 | 0 | 0 | 21 | 17 | 15 | 9 |
|
| | 90.7 | 36.8 | -100.0 | | | -28.7 | -2.3 | -43.4 |
| 6.8 | 8.8 | 9.4 | | | 7.3 | 5.2 | 4.5 | 2.4 |
| 5.5 | 10.4 | 12.3 | 13.4 | 18.7 | 20.0 | 14.0 | 13.2 | 7.5 |
| Financial Year | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|
Equity Capital Equity CapitalCr | 20 | 20 | 23 | 0 | 0 | 25 | 26 | 26 | 26 |
| 30 | 50 | 133 | 0 | 0 | 458 | 734 | 763 | 773 |
Current Liabilities Current LiabilitiesCr | 84 | 117 | 150 | 0 | 0 | 410 | 527 | 733 | 837 |
Non Current Liabilities Non Current LiabilitiesCr | 46 | 60 | 49 | 0 | 0 | 162 | 174 | 225 | 665 |
Total Liabilities Total LiabilitiesCr |
Current Assets Current AssetsCr | 107 | 160 | 231 | 0 | 0 | 656 | 784 | 1,000 | 1,319 |
Non Current Assets Non Current AssetsCr | 74 | 87 | 124 | 0 | 0 | 398 | 678 | 747 | 983 |
Total Assets Total AssetsCr |
| Financial Year | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|
Operating Cash Flow Operating Cash FlowCr | 12 | -4 | -35 | 84 | 1 | -30 | -29 | 196 |
Investing Cash Flow Investing Cash FlowCr | -13 | -20 | -29 | -135 | -146 | -94 | -216 | -317 |
Financing Cash Flow Financing Cash FlowCr | 0 | 24 | 63 | 51 | 188 | 100 | 237 | 113 |
|
Free Cash Flow Free Cash FlowCr | -2 | -22 | -61 | 61 | -169 | -133 | -332 | -121 |
| 107.9 | -17.6 | -120.6 | | | -60.7 | -81.8 | 562.7 |
CFO To EBITDA CFO To EBITDA% | 40.9 | -8.5 | -59.5 | | | -27.2 | -26.5 | 143.8 |
| Financial Year | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|
Valuation Ratios Valuation Ratios |
Market Cap Market CapitalizationCr | 0 | 0 | 819 | 2,017 | 4,352 | 3,200 | 3,147 | 4,076 |
Price To Earnings Price To Earnings | 0.0 | 0.0 | 28.6 | 64.4 | 97.5 | 64.0 | 88.3 | 117.0 |
Price To Sales Price To Sales | 0.0 | 0.0 | 2.7 | 6.0 | 8.9 | 4.7 | 4.6 | 5.2 |
Price To Book Price To Book | 0.0 | 0.0 | 5.2 | 11.0 | 9.9 | 6.6 | 4.1 | 5.2 |
| 2.7 | 2.6 | 16.4 | | | 31.8 | 32.2 | 34.2 |
Profitability Ratios Profitability Ratios |
| 41.1 | 41.1 | 39.9 | | | 43.4 | 44.6 | 45.6 |
| 18.0 | 18.2 | 19.0 | | | 16.3 | 15.9 | 17.5 |
| 6.8 | 8.8 | 9.4 | | | 7.3 | 5.2 | 4.5 |
| 21.4 | 22.1 | 18.4 | | | 11.7 | 8.1 | 7.1 |
| 21.8 | 29.8 | 18.3 | | | 10.4 | 4.7 | 4.4 |
| 6.1 | 8.5 | 8.1 | | | 4.7 | 2.4 | 2.0 |
Operational Ratios Operational Ratios |
Solvency Ratios Solvency Ratios |
Liquidity Ratios Liquidity Ratios |
### **Overview**
Neogen Chemicals Limited, founded in 1989 and headquartered in India, is a leading manufacturer of bromine- and lithium-based specialty chemicals. With over 35 years of experience, the company has evolved from a niche player to a globally recognized supplier serving high-value industries such as pharmaceuticals, agrochemicals, electronics, polymers, construction, and increasingly, energy storage and electric vehicles (EVs). As of November 2025, Neogen is actively transforming into a **technology-driven, agile specialty chemicals leader**, with a strategic focus on the **lithium-ion battery materials value chain**.
---
### **Core Business Segments**
Neogen operates across four main chemical domains:
1. **Bromine Compounds**: Organic derivatives containing bromine, chlorine, fluorine, iodine, and Grignard reagents used in pharmaceuticals, agrochemicals, and electronic chemicals.
2. **Organolithium/ Organometallic Products**: Key reagents such as *n-Butyl Lithium (BuLi)* for lithiation reactions in complex synthesis; critical in pharma, agrochemicals, and semiconductor manufacturing.
3. **Advanced Intermediates**: Multi-step bromination-based chemical solutions that deliver forward-integrated, high-value products used in APIs, agrochemicals, and specialty polymers.
4. **Custom Synthesis & Contract Manufacturing (CSM)**: Tailored chemical solutions developed in-house for global clients across pharma, agrochemicals, flavors, fragrances, and electronics sectors.
Its inorganic chemicals portfolio includes **specialty lithium-based products** with applications in eco-friendly VAM (Vapor Absorption Chillers), construction, and increasingly, battery technologies.
---
### **Strategic Growth: Entry into Battery Materials**
Neogen has positioned itself as a first-mover in India’s emerging lithium-ion battery ecosystem, driven by rising EV adoption, government incentives (e.g., PLI Scheme), and global demand for non-Chinese supply chains.
#### **Neogen Ionics Limited (NIL) – Wholly-Owned Subsidiary**
Established in 2023, **Neogen Ionics Limited** is the dedicated arm for battery materials. It focuses on:
- Solid LiPF₆ (lithium hexafluorophosphate) salt
- Electrolyte formulation
- Additives and services for advanced chemistry cell (ACC) batteries
NIL is developing **India's largest integrated battery materials plant** at **Pakhajan, Dahej PCPIR (Gujarat)**, with full backward integration from lithium carbonate to finished electrolytes.
#### **Key Projects & Capacity Expansion (FY25–FY27)**
| Facility | Location | Planned Capacity | Technology Source |
|--------|--------|------------------|-------------------|
| Greenfield Electrolyte Plant | Pakhajan, Dahej PCPIR | 30,000 MT/year | Licensed from MUIS (Japan) |
| Greenfield Lithium Electrolyte Salt Plant | Pakhajan, Dahej PCPIR | 3,000 MT/year | Proprietary in-house tech |
| Dahej SEZ Expansion | Dahej, Gujarat | +400 MT salt; +2,000 MT electrolyte | Indigenous + MUIS |
| **Total Combined Capacity** | Across Dahej sites | **32,000 MT electrolyte**, **5,500 MT lithium salts/additives** | - |
| **CAPEX Investment** | | ₹1,500 Crore | Debt-financed; project finance secured |
- **Commercial Timelines (Nov 2025 Status):**
- Electrolyte production expected by **1H FY27** (April–September 2026)
- Lithium salt production delayed to **2H FY27** due to technology homologation with Japanese partners
- Mechanical completion of Pakhajan greenfield plant expected by **end of 2025**
- **Peak Revenue Potential:** INR **2,500–2,950 crore by FY29**, contingent on lithium prices and global off-take.
---
### **Strategic Partnerships**
Neogen has formed key alliances to accelerate its transition into the battery sector:
- **MU Ionic Solutions Corporation (MUIS, Japan):** Secured an **exclusive technology license** to manufacture high-quality lithium-ion battery electrolytes — the **first ever granted globally by MUIS**. This gives Neogen a first-mover advantage and alignment with global quality and safety standards.
- **Morita Chemical Industries (Japan):** Entered into a **landmark Indo-Japan joint venture** through **Neogen Morita New Materials Limited (NML)**, aiming to scale up LiPF₆ electrolyte salt production. Morita brings 30+ years of experience in large-scale salt manufacturing, enhancing production know-how, process safety, and international customer approvals.
This J-V makes Neogen the **first Indo-Japan JV in the battery materials space**, signaling strong global interest in the India+1 supply chain initiative.
---
### **Technology & R&D Capabilities**
- **R&D Units:** Two dedicated centers in **Mahape (Navi Mumbai)** and **Vadodara**, established since 2001.
- **Team:** 116-member R&D team including **11 PhD scientists**; ~13% of workforce dedicated to R&D.
- **Leadership Involvement:** Managing Director **Dr. Harin Kanani** (PhD, University of Maryland) directly oversees R&D.
- **Portfolio Growth:** Expanded from **20 products in 2001** to **258 products by Q2 FY26**.
- **Focus Areas:** Complex chemistries including lithiation, Grignard reactions, Suzuki coupling, biocatalysis, flow chemistry, and high-vacuum distillation.
- **Innovation:** Strong emphasis on **in-house process know-how**, custom molecule development, and **lithium recycling from by-products**.
---
### **Manufacturing Infrastructure**
- **Six Manufacturing Sites:** Mahape (Navi Mumbai), Karakhadi & Vadodara (Gujarat), Dahej SEZ (Gujarat), Patancheru (Hyderabad), and a new **65-acre greenfield site at Pakhajan, Dahej PCPIR**.
- **Reactor Capacity (FY24–25):**
- Organic chemicals: **438 m³**
- Inorganic chemicals: **39 metric tons**
- **Patancheru Facility Expansion:** After acquisition of BuLi Chem, de-bottlenecking increased organolithium capacity from **120 to 300 MTPA**.
- **Certifications:** ISO 9001, ISO 14001, ISO 45001, and compliance with US FDA cGMP standards.
---
### **Growth Enablers & Competitive Advantages**
1. **First-Mover Advantage in Battery Materials:**
- One of only **2–3 non-Chinese LiPF₆ salt producers globally**.
- Exclusive access to **MUIS technology**, offering quality assurance and faster customer approvals.
- India’s **first company to be PPAP-certified** by a leading giga-scale Indian battery manufacturer — marking a major milestone in supply chain integration.
2. **Vertical Integration & Supply Chain Security:**
- **Backward integration** into organolithium and electrolyte salt production.
- **Lithium recycling** capabilities reduce raw material costs and environmental footprint.
- Long-term supply agreements with **top 2–3 global lithium miners**; dominant importer of **lithium carbonate & hydroxide** in India.
3. **China+1 Strategy Beneficiary:**
- Strong global interest from **OEMs and cell makers** seeking **IRA-compliant, non-FEOC (Foreign Entity of Concern)** supply chains.
- Positioning as a **low-cost, reliable alternative outside China**.
4. **Custom Synthesis Momentum:**
- Over 258 products offered; strong traction in pharma and electronics.
- Export contracts with **EU, U.S., Japan, Korea, Middle East**.
- Growing CSM revenue stream with long-term supply agreements.
5. **Government Support:**
- Benefiting from **PLI Scheme for ACC batteries**, **zero customs duty on lithium**, and "Make in India" initiatives.
---
### **Recent Key Milestones (Nov 2025 Update)**
- Received **PPAP certification** from a major Indian giga-scale battery manufacturer — a rare achievement in India.
- Secured **provisional approval** from a **major international customer** for lithium electrolyte salt (final approval expected Q4 FY26).
- **Sample batches approved** by several global clients; commercial supply ongoing for early customers.
- Dahej SEZ facility already producing **trial and early commercial volumes** of electrolytes and salts.
- **Strategic land acquisition** of **270,740 m² across Dahej and Pakhajan** for future expansion.